1. Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell lines. MCF7, MDA-MB-231, MDA-MB-436, and HCC-1937 cells were treated with the indicated concentrations of trabectedin, olaparib or the combination of both drugs for 24 hours. Then, each cell line was lysed and analyzed by western blot with anti-PAR and γ-H2AX antibodies. α-Tubulin was used as loading control. NT=non-treated cells; C1=combination of 0.05 nM trabectedin and 5 µM olaparib; C2=combination of 0.1 nM trabectedin and 5 µM olaparib; C3=combination of 0.5 nM trabectedin and 5 µM olaparib.
Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell lines. MCF7, MDA-MB-231, MDA-MB-436, and HCC-1937 cells were treated with the indicated concentrations of trabectedin, olaparib or the combination of both drugs for 24 hours. Then, each cell line was lysed and analyzed. . .
J Breast Cancer Dec;18(4):